Abstract
Vancomycin-resistant enterococci (VRE) are major health care-associated pathogens and significantly contribute to patient morbidity and mortality, particularly in immunocompromised and critically ill patients. The clinical management of VRE infections is challenging due to limited therapeutic options and the paucity of high quality clinical data to guide management. Delays in initiating appropriate therapy has proven to have significant impact in VRE-associated bloodstream infections. This review summarizes the current evidence on treatment strategies for serious VRE infections, incluiding bacteremia and endocarditis, as well as emerging treatment strategies for these recalcitrant organisms.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 183-203 |
| Number of pages | 21 |
| Journal | Infectious Disease Clinics of North America |
| Volume | 40 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2026 |
Keywords
- Bacteremia
- Daptomycin
- Endocarditis
- Enterococci
- Health care-acquired infection
- Linezolid
- Multidrug-resistant microorganisms
- VRE (vancomycin-resistant enterococci)
- Humans
- Endocarditis, Bacterial/drug therapy
- Cross Infection/drug therapy
- Vancomycin/therapeutic use
- Bacteremia/drug therapy
- Gram-Positive Bacterial Infections/drug therapy
- Anti-Bacterial Agents/therapeutic use
- Vancomycin-Resistant Enterococci/drug effects
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Current Management of Serious Infections due to Vancomycin-resistant Enterococci'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS